FDA Recalls Nationwide Supply of Erythromycin Ophthalmic Ointment for Manufacturing Deviations
Akorn, Inc. is recalling 36,455 cartons of Erythromycin Ophthalmic Ointment USP 0.5% nationwide due to manufacturing process deviations. The company voluntarily initiated this Class II recall.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall based on manufacturing process deviations that could affect product quality and safety. Although no illnesses or injuries have been reported, the lack of compliance with manufacturing standards poses a potential risk of harm to patients using the ophthalmic ointment.
Plain-English summary
Akorn, Inc. is recalling Erythromycin Ophthalmic Ointment USP 0.5% (NDC 17478-070-31) due to current good manufacturing practice (CGMP) deviations. The recall affects 36,455 cartons distributed nationwide in the United States. This is a voluntary Class II recall initiated by the company on October 13, 2022, and classified by the FDA on January 13, 2023. No illnesses or injuries have been reported.
The following lot numbers are affected with their expiration dates: Lot 1B14B (1/31/2023); Lots 1C49A, 1C49B, 1C70A (2/28/2023); Lots 1E09A, 1E34A, 1E34B, 1E09B (4/30/2023); Lots 1F37C, 1F37A, 1F37B (5/31/2023); Lots 1G58A, 1G57B, 1G58B, 1G66B, 1G66A, 1G57A (6/30/2023); Lots 1H77B, 1H80A, 1H80B, 1H77A (7/31/2023); Lot 1J24A (8/31/2023); Lots 1K67B, 1K67A, 1K76A, 1K87B, 1K77A, 1K76B, 1K87A, 1K77B (9/30/2023); Lots 1L90B, 1L90A, 1L92B, 1L92A (10/31/2023); Lots 1M28A, 1M35A, 1M28B (11/30/2023); and Lot 2D20B (3/31/2024).
Healthcare providers and patients should stop using the recalled product. Those with questions or concerns about adverse effects should contact Akorn, Inc. or the FDA. The recall is ongoing.
The recalled product
- Product
- Erythromycin Ophthalmic Ointment USP, 0.5%, Net Weight: 1 g per tube (50 unit-dose tubes per carton), Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. NDC: 17478-070-31
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 36,455
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 1B14B
- EXP 1/31/2023
- 1C49A
- 1C49B
- 1C70A
- EXP 2/28/2023
- 1E09A
- 1E34A
- 1E34B
- 1E09B
- EXP 4/30/2023
- 1F37C
- 1F37A
- 1F37B
- EXP 5/31/2023
- 1G58A
- 1G57B
- 1G58B
- 1G66B
- 1G66A
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 27 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 27 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · manufacturing defect
See all →- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-09-09
- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- HighKnee Prosthesis Trial Recall for Manufacturing Defect
FDA (Devices) · 2026-08-12
- HighUSTAR II Knee System Hinge Box Trial Recall
FDA (Devices) · 2026-08-12
- HighU2 Total Knee System Femoral Valgus Adaptor Recall
FDA (Devices) · 2026-08-12